Research progress of targeting NOD-like receptor family Pyrin domain containing 3 inflammasome for the treatment of experimental MAFLD-associated liver fibrosis
Metabolic dysfunction-associated fatty liver disease(MAFLD)is becoming an leading causes of hepatic fibrosis worldwide,resulting in MAFLD-related liver fibrosis.Emerging evidences have indicated that the activation of the NOD-like receptor family Pyrin domain containing 3(NLRP3)inflammasome is a critical contributor to the development of MAFLD-related liver fibrosis.This article reviews the mechanism by which NLRP3 inflammasome activation promotes the development of MAFLD-related liver fibrosis,and focuses on the pharmacological mechanism of drugs targeting NLRP3 inflammasome to treat MAFLD-related liver fibrosis.
NETL
NSTL
万方数据
